IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 13, 2021 | Series B | €127M | 1 | — | — | Detail |
Jan 5, 2016 | Series A | €11M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lundbeckfonden Emerge | — | Series B |
Novo Nordisk | — | Series A |